Taiwan’s cancer focused Anbogen raises $12.5M in series A round

Feb. 6, 2024

Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.

Taiwan’s cancer focused Anbogen raises $12.5M in series A round

Feb. 2, 2024

By Marian (YoonJee) Chu

Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...